Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 LIMITATIONS
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 ASIA-PACIFIC STROKE MARKET, REGULATORY FRAMEWORK
5.1 REGULATION IN U.S.
5.2 REGULATION IN EUROPE
5.3 REGULATION IN CHINA
5.4 REGULATION IN JAPAN
5.5 REGULATION IN SOUTH AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS
6.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES
6.1.3 INCREASING DIABETIC AND OBESE POPULATIONS ELEVATE STROKE RISKS
6.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY IMPROVE STROKE CARE OUTCO.MES
6.2 RESTRAINTS
6.2.1 HIGH COST OF DIAGNOSIS
6.2.2 INCREASE IN PRODUCT RECALL
6.3 OPPORTUNITIES
6.3.1 DEVELOPMENT OF ADVANCED THERAPEUTICS FOR STROKES
6.3.2 EXPANSION IN STROKE REHABILITATION SERVICES
6.3.3 INNOVATIVE TREATMENTS IN PIPELINE FOR STROKE TREATMENT
6.4 CHALLENGES
6.4.1 FALSE DIAGNOSIS IN STROKES
6.4.2 COMPLICATIONS ASSOCIATED WITH MANAGING STROKE
7 ASIA-PACIFIC STROKE MARKET, BY TYPE
7.1 OVERVIEW
7.2 ISCHEMIC STROKE
7.2.1 THROMBOTIC (CEREBRAL THROMBOSIS)
7.2.2 EMBOLIC (CEREBRAL EMBOLISM)
7.3 HEMORRHAGIC STROKE
7.3.1 SUBARACHNOID HEMORRHAGE
7.3.2 INTRACEREBRAL HEMORRHAGE
7.4 TRANSIENT ISCHEMIC ATTACT (TIA)
8 ASIA-PACIFIC STROKE MARKET, BY GENDER
8.1 OVERVIEW
8.2 FEMALE
8.3 MALE
9 ASIA-PACIFIC STROKE MARKET, BY DIAGNOSIS AND TREATMENT
9.1 OVERVIEW
9.2 TREATMENT
9.2.1 BY TREATMENT TYPE
9.2.1.1 MEDICATION
9.2.1.1.1 MEDICATION, BY CLASS
9.2.1.1.1.1 BLOOD PRESSURE MEDICINES
9.2.1.1.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
9.2.1.1.1.1.2 RAMIPRIL
9.2.1.1.1.1.3 LISINOPRIL
9.2.1.1.1.1.4 ENALAPRIL
9.2.1.1.1.1.5 PERINDOPRIL
9.2.1.1.1.1.6 OTHER
9.2.1.1.1.2 THIAZIDE DIURETICS
9.2.1.1.1.2.1 INDAPAMIDE
9.2.1.1.1.2.2 BENDROFLUMETHIAZIDE
9.2.1.1.1.2.3 SPIRONOLACTONE
9.2.1.1.1.2.4 AMILORIDE
9.2.1.1.1.2.5 OTHER
9.2.1.1.1.3 CALCIUM CHANNEL BLOCKERS
9.2.1.1.1.3.1 AMLODIPINE
9.2.1.1.1.3.2 NIFEDIPINE
9.2.1.1.1.3.3 VERAPAMIL
9.2.1.1.1.3.4 NICARDIPINE
9.2.1.1.1.3.5 FELODIPINE
9.2.1.1.1.3.6 NIMODIPINE
9.2.1.1.1.3.7 OTHERS
9.2.1.1.1.4 BETA BLOCKERS
9.2.1.1.1.4.1 ATENOLOL
9.2.1.1.1.4.2 BISOPROLOL
9.2.1.1.1.4.3 LABETOLOL
9.2.1.1.1.4.4 OTHERS
9.2.1.1.1.5 ALPHA-BLOCKERS
9.2.1.1.1.5.1 DOXAZOSIN
9.2.1.1.1.5.2 OTHERS
9.2.1.1.1.6 OTHERS
9.2.1.1.1.7 ANTIPLATELET DRUGS
9.2.1.1.1.7.1 ASPIRIN
9.2.1.1.1.7.2 CLOPIDOGREL
9.2.1.1.1.7.3 DIPYRIDAMOLE
9.2.1.1.1.7.4 TICLOPIDINE
9.2.1.1.1.7.5 OTHERS
9.2.1.1.1.8 ANTICOAGULANTS
9.2.1.1.1.8.1 WARFARIN
9.2.1.1.1.8.2 APIXABAN
9.2.1.1.1.8.3 DABIGATRAN
9.2.1.1.1.8.4 HEPARIN
9.2.1.1.1.8.5 RIVAROXABAN
9.2.1.1.1.8.6 OTHERS
9.2.1.1.1.9 TISSUE PLASMINOGEN ACTIVATOR (TPA)
9.2.1.1.1.9.1 ALTEPLASE
9.2.1.1.1.9.2 TENECTEPLASE
9.2.1.1.1.9.3 RETEPLASE
9.2.1.1.1.9.4 ANISTREPLASE
9.2.1.1.1.9.5 OTHERS
9.2.1.1.1.10 STATINS
9.2.1.1.1.10.1.1 ATORVASTATIN
9.2.1.1.1.10.1.2 SIMVASTATIN
9.2.1.1.1.10.1.3 LOVASTATIN
9.2.1.1.1.10.1.4 ROSUVASTATIN
9.2.1.1.1.10.1.5 FLUVASTATIN
9.2.1.1.1.10.1.6 PRAVASTATIN
9.2.1.1.1.10.1.7 PITAVASTATIN
9.2.1.1.1.10.1.8 OTHERS
9.2.1.1.1.11 VITAMIN K
9.2.1.1.1.12 SUPPORTIVE MEDICATION
9.2.1.1.1.12.1 NUTRITIONAL SUPPLEMENTS
9.2.1.1.1.12.2 ANTIPYRETICS
9.2.1.1.1.12.3 OTHERS
9.2.1.1.2 MEDICATION, BY DRUG TYPE
9.2.1.1.2.1 BRANDED
9.2.1.1.2.1.1 ACTIVASE
9.2.1.1.2.1.2 EDOBAXAN
9.2.1.1.2.1.3 COUMADIN
9.2.1.1.2.1.4 HEPARIN LEO
9.2.1.1.2.1.5 DUOPLAVIN
9.2.1.1.2.1.6 AGGRENOX
9.2.1.1.2.1.7 RETAVASE
9.2.1.1.2.1.8 JANTOVEN
9.2.1.1.2.1.9 CATHFLO
9.2.1.1.2.1.10 OTHER
9.2.1.1.2.2 GENERIC
9.2.1.1.3 MEDICATION, BY ROUTE OF ADMINISTRATION
9.2.1.1.3.1 ORAL
9.2.1.1.3.1.1 TABLET
9.2.1.1.3.1.2 CAPSULES
9.2.1.1.3.1.3 OTHERS
9.2.1.1.3.2 PARENTERAL
9.2.1.1.3.2.1 INTRAVENOUS
9.2.1.1.3.2.2 SUBCUTANEOUS
9.2.1.1.3.3 OTHERS
9.2.1.1.4 MEDICATION, BY MODE OF PURCHASE
9.2.1.1.4.1 PRESCRIPTION
9.2.1.1.4.2 OVER THE COUNTER (OTC)
9.2.1.1.5 MEDICATION, BY THERAPY TYPE
9.2.1.1.5.1 COMBINATION THERAPY
9.2.1.1.5.2 MONOTHERAPY
9.2.1.2 SURGERY
9.2.1.2.1 EMBOLIC COILS
9.2.1.2.2 ASPIRATION CATHETERS
9.2.1.2.3 STENT RETRIEVER
9.2.1.2.4 SURGICAL CLIPPING
9.2.1.2.5 OTHERS
9.2.1.3 OTHERS THERAPY
9.2.1.3.1 PHYSICAL THERAPY
9.2.1.3.2 OCCUPATIONAL THERAPY
9.2.1.3.3 SPEECH THERAPY
9.2.1.3.4 OTHERS
9.3 DIAGNOSIS
9.3.1 IMAGING TEST
9.3.1.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN
9.3.1.2 MAGNETIC RESONANCE IMAGING (MRI)
9.3.1.3 CAROTID ULTRASOUND
9.3.1.4 CEREBRAL ANGIOGRAM
9.3.2 BLOOD TEST
9.3.3 ECHOCARDIOGRAM
9.3.4 LUMBAR PUNCTURE
9.3.5 OTHERS
10 ASIA-PACIFIC STROKE MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT
10.3 RETAIL
10.4 ONLINE
11 ASIA-PACIFIC STROKE MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS & CLINICS
11.3 SPECIALTY CLINICS
11.4 AMBULATORY SURGICAL CENTER
11.5 HOMECARE
11.6 LABORATORIES
11.7 OTHERS
12 ASIA-PACIFIC STROKE MARKET, BY REGION
12.1 ASIA-PACIFIC
12.1.1 CHINA
12.1.2 JAPAN
12.1.3 INDIA
12.1.4 AUSTRALIA
12.1.5 SOUTH KOREA
12.1.6 SINGAPORE
12.1.7 THAILAND
12.1.8 PHILIPPINES
12.1.9 MALAYSIA
12.1.10 INDONESIA
12.1.11 VIETNAM
12.1.12 TAIWAN
12.1.13 REST OF ASIA-PACIFIC
13 ASIA-PACIFIC STROKE MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 BRISTOL-MYERS SQUIBB COMPANY
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.2 F. HOFFMANN-LA ROCHE LTD
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 DAIICHI SANKYO COMPANY, LIMITED
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 SANOFI
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AMNEAL PHARMACEUTICALS LLC
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ASTRAZENECA
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BAYER AG
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 FRESENIUS SE & CO. KGAA
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 GLENMARK PHARMACEUTICALS LTD.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 JOHNSON & JOHNSON SERVICES, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 LUPIN
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.14 MEDTRONIC
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 PENUMBRA, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 PFIZER INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 SANDOZ AG
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 TEVA PHARMACEUTICALS USA, INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENT
15.19 VIATRIS INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 ASIA-PACIFIC STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 ASIA-PACIFIC ISCHEMIC STROKE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC HEMORRHAGIC STROKE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC TRANSIENT ISCHEMIC ATTACT (TIA) IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC FEMALE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC MALE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC TREATMENT IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC BLOOD PRESSURE MEDICINES IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC DIAGNOSIS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 38 ASIA-PACIFIC DIRECT IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 ASIA-PACIFIC RETAIL IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 ASIA-PACIFIC ONLINE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 ASIA-PACIFIC STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 42 ASIA-PACIFIC HOSPITALS & CLINICS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 43 ASIA-PACIFIC SPECIALTY CLINICS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 ASIA-PACIFIC AMBULATORY SURGICAL CENTER IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 ASIA-PACIFIC HOMECARE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 ASIA-PACIFIC LABORATORIES IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 ASIA-PACIFIC OTHERS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 ASIA-PACIFIC STROKE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 49 ASIA-PACIFIC STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 ASIA-PACIFIC HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 ASIA-PACIFIC STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 53 ASIA-PACIFIC TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 55 ASIA-PACIFIC BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 56 ASIA-PACIFIC ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 57 ASIA-PACIFIC THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 59 ASIA-PACIFIC BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 60 ASIA-PACIFIC ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 61 ASIA-PACIFIC ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 62 ASIA-PACIFIC ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 63 ASIA-PACIFIC TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 64 ASIA-PACIFIC STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 65 ASIA-PACIFIC SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 66 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 ASIA-PACIFIC BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 69 ASIA-PACIFIC ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 ASIA-PACIFIC PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 72 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 ASIA-PACIFIC SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 ASIA-PACIFIC OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 ASIA-PACIFIC DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 ASIA-PACIFIC IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 ASIA-PACIFIC STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 78 ASIA-PACIFIC STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 79 ASIA-PACIFIC STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 80 CHINA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 CHINA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 CHINA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 CHINA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 84 CHINA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 CHINA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 86 CHINA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 87 CHINA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 88 CHINA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 89 CHINA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 90 CHINA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 91 CHINA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 92 CHINA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 93 CHINA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 94 CHINA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 95 CHINA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 96 CHINA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 97 CHINA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 CHINA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 CHINA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 100 CHINA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 CHINA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 CHINA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 103 CHINA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 CHINA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 CHINA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 CHINA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 CHINA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 CHINA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 109 CHINA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 110 CHINA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 111 JAPAN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 JAPAN ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 JAPAN HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 JAPAN STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 115 JAPAN TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 JAPAN MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 117 JAPAN BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 118 JAPAN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 119 JAPAN THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 120 JAPAN CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 121 JAPAN BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 122 JAPAN ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 123 JAPAN ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 124 JAPAN ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 125 JAPAN TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 126 JAPAN STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 127 JAPAN SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 128 JAPAN MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 JAPAN BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 JAPAN MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 131 JAPAN ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 JAPAN PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 JAPAN MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 134 JAPAN MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 JAPAN SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 JAPAN OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 JAPAN DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 JAPAN IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 JAPAN STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 140 JAPAN STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 141 JAPAN STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 142 INDIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 INDIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 INDIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 INDIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 146 INDIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 INDIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 148 INDIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 149 INDIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 150 INDIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 151 INDIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 152 INDIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 153 INDIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 154 INDIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 155 INDIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 156 INDIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 157 INDIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 158 INDIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 159 INDIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 INDIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 INDIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 162 INDIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 INDIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 INDIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 165 INDIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 INDIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 INDIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 INDIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 INDIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 INDIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 171 INDIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 172 INDIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 173 AUSTRALIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 174 AUSTRALIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 AUSTRALIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 AUSTRALIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 177 AUSTRALIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 AUSTRALIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 179 AUSTRALIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 180 AUSTRALIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 181 AUSTRALIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 182 AUSTRALIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 183 AUSTRALIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 184 AUSTRALIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 185 AUSTRALIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 186 AUSTRALIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 187 AUSTRALIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 188 AUSTRALIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 189 AUSTRALIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 190 AUSTRALIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 AUSTRALIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 AUSTRALIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 193 AUSTRALIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 AUSTRALIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 AUSTRALIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 196 AUSTRALIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 AUSTRALIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 AUSTRALIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 AUSTRALIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 AUSTRALIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 AUSTRALIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 202 AUSTRALIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 203 AUSTRALIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 204 SOUTH KOREA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 SOUTH KOREA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 SOUTH KOREA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 SOUTH KOREA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 208 SOUTH KOREA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 SOUTH KOREA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 210 SOUTH KOREA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 211 SOUTH KOREA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 212 SOUTH KOREA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 213 SOUTH KOREA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 214 SOUTH KOREA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 215 SOUTH KOREA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 216 SOUTH KOREA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 217 SOUTH KOREA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 218 SOUTH KOREA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 219 SOUTH KOREA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 220 SOUTH KOREA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 221 SOUTH KOREA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 SOUTH KOREA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 SOUTH KOREA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 224 SOUTH KOREA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 SOUTH KOREA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 SOUTH KOREA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 227 SOUTH KOREA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 SOUTH KOREA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 SOUTH KOREA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 SOUTH KOREA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 SOUTH KOREA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 SOUTH KOREA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 233 SOUTH KOREA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 234 SOUTH KOREA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 235 SINGAPORE STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 236 SINGAPORE ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 SINGAPORE HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 SINGAPORE STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 239 SINGAPORE TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 SINGAPORE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 241 SINGAPORE BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 242 SINGAPORE ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 243 SINGAPORE THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 244 SINGAPORE CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 245 SINGAPORE BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 246 SINGAPORE ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 247 SINGAPORE ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 248 SINGAPORE ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 249 SINGAPORE TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 250 SINGAPORE STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 251 SINGAPORE SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 252 SINGAPORE MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 SINGAPORE BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 SINGAPORE MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 255 SINGAPORE ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 SINGAPORE PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 SINGAPORE MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 258 SINGAPORE MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 SINGAPORE SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 SINGAPORE OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 SINGAPORE DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 SINGAPORE IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 263 SINGAPORE STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 264 SINGAPORE STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 265 SINGAPORE STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 266 THAILAND STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 THAILAND ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 THAILAND HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 THAILAND STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 270 THAILAND TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 271 THAILAND MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 272 THAILAND BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 273 THAILAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 274 THAILAND THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 275 THAILAND CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 276 THAILAND BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 277 THAILAND ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 278 THAILAND ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 279 THAILAND ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 280 THAILAND TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 281 THAILAND STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 282 THAILAND SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 283 THAILAND MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 THAILAND BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 THAILAND MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 286 THAILAND ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 THAILAND PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 288 THAILAND MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 289 THAILAND MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 THAILAND SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 291 THAILAND OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 292 THAILAND DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 THAILAND IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 THAILAND STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 295 THAILAND STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 296 THAILAND STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 297 PHILIPPINES STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 PHILIPPINES ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 PHILIPPINES HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 PHILIPPINES STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 301 PHILIPPINES TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 PHILIPPINES MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 303 PHILIPPINES BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 304 PHILIPPINES ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 305 PHILIPPINES THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 306 PHILIPPINES CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 307 PHILIPPINES BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 308 PHILIPPINES ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 309 PHILIPPINES ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 310 PHILIPPINES ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 311 PHILIPPINES TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 312 PHILIPPINES STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 313 PHILIPPINES SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 314 PHILIPPINES MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 315 PHILIPPINES BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 316 PHILIPPINES MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 317 PHILIPPINES ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 318 PHILIPPINES PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 PHILIPPINES MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 320 PHILIPPINES MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 321 PHILIPPINES SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 322 PHILIPPINES OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 PHILIPPINES DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 PHILIPPINES IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 PHILIPPINES STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 326 PHILIPPINES STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 327 PHILIPPINES STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 328 MALAYSIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 MALAYSIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 330 MALAYSIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 MALAYSIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 332 MALAYSIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 MALAYSIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 334 MALAYSIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 335 MALAYSIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 336 MALAYSIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 337 MALAYSIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 338 MALAYSIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 339 MALAYSIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 340 MALAYSIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 341 MALAYSIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 342 MALAYSIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 343 MALAYSIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 344 MALAYSIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 345 MALAYSIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 MALAYSIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 347 MALAYSIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 348 MALAYSIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 349 MALAYSIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 MALAYSIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 351 MALAYSIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 MALAYSIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 353 MALAYSIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 MALAYSIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 MALAYSIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 MALAYSIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 357 MALAYSIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 358 MALAYSIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 359 INDONESIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 360 INDONESIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 INDONESIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 INDONESIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 363 INDONESIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 364 INDONESIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 365 INDONESIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 366 INDONESIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 367 INDONESIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 368 INDONESIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 369 INDONESIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 370 INDONESIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 371 INDONESIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 372 INDONESIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 373 INDONESIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 374 INDONESIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 375 INDONESIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 376 INDONESIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 377 INDONESIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 378 INDONESIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 379 INDONESIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 380 INDONESIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 381 INDONESIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 382 INDONESIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 INDONESIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 384 INDONESIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 385 INDONESIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 386 INDONESIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 INDONESIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 388 INDONESIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 389 INDONESIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 390 VIETNAM STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 391 VIETNAM ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 392 VIETNAM HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 VIETNAM STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 394 VIETNAM TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 395 VIETNAM MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 396 VIETNAM BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 397 VIETNAM ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 398 VIETNAM THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 399 VIETNAM CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 400 VIETNAM BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 401 VIETNAM ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 402 VIETNAM ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 403 VIETNAM ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 404 VIETNAM TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 405 VIETNAM STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 406 VIETNAM SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 407 VIETNAM MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 VIETNAM BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 VIETNAM MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 410 VIETNAM ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 VIETNAM PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 VIETNAM MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 413 VIETNAM MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 414 VIETNAM SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 VIETNAM OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 VIETNAM DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 VIETNAM IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 418 VIETNAM STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 419 VIETNAM STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 420 VIETNAM STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 421 TAIWAN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 TAIWAN ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 TAIWAN HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 424 TAIWAN STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 425 TAIWAN TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 TAIWAN MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 427 TAIWAN BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 428 TAIWAN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 429 TAIWAN THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 430 TAIWAN CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 431 TAIWAN BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 432 TAIWAN ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 433 TAIWAN ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 434 TAIWAN ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 435 TAIWAN TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 436 TAIWAN STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 437 TAIWAN SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 438 TAIWAN MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 439 TAIWAN BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 TAIWAN MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 441 TAIWAN ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 442 TAIWAN PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 TAIWAN MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 444 TAIWAN MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 445 TAIWAN SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 446 TAIWAN OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 447 TAIWAN DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 448 TAIWAN IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 449 TAIWAN STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 450 TAIWAN STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 451 TAIWAN STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 452 REST OF ASIA-PACIFIC STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 ASIA-PACIFIC STROKE MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC STROKE MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC STROKE MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC STROKE MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC STROKE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC STROKE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC STROKE MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC STROKE MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 ASIA-PACIFIC STROKE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC STROKE MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS IS EXPECTED TO DRIVE THE ASIA-PACIFIC STROKE MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 12 ISCHEMIC STROKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC STROKE MARKET IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 13 ASIA-PACIFIC STROKE MARKET EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC STROKE MARKET
FIGURE 16 ASIA-PACIFIC STROKE MARKET: BY TYPE, 2024
FIGURE 17 ASIA-PACIFIC STROKE MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 18 ASIA-PACIFIC STROKE MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 19 ASIA-PACIFIC STROKE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC STROKE MARKET: BY GENDER, 2024
FIGURE 21 ASIA-PACIFIC STROKE MARKET: BY GENDER, 2025 TO 2032 (USD THOUSAND)
FIGURE 22 ASIA-PACIFIC STROKE MARKET: BY GENDER, CAGR (2025- 2032)
FIGURE 23 ASIA-PACIFIC STROKE MARKET: BY GENDER, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC STROKE MARKET: BY DIAGNOSIS AND TREATMENT, 2024
FIGURE 25 ASIA-PACIFIC STROKE MARKET: BY DIAGNOSIS AND TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 26 ASIA-PACIFIC STROKE MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2025-2032)
FIGURE 27 ASIA-PACIFIC STROKE MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC STROKE MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 29 ASIA-PACIFIC STROKE MARKET: BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
FIGURE 30 ASIA-PACIFIC STROKE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 31 ASIA-PACIFIC STROKE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC STROKE MARKET: BY END USER, 2024
FIGURE 33 ASIA-PACIFIC STROKE MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 34 ASIA-PACIFIC STROKE MARKET: BY END USER, CAGR (2025-2032)
FIGURE 35 ASIA-PACIFIC STROKE MARKET: BY END USER, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC STROKE MARKET: SNAPSHOT (2024)
FIGURE 37 ASIA-PACIFIC STROKE MARKET: COMPANY SHARE 2024 (%)
